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In January 2012, the presence of John Cunningham virus
(JCV) antibodies was incorporated into the US prescribing
information for Tysabri® (natalizumab) as a third independent
risk factor for progressive multifocal leukoencephalopathy
(PML) development in natalizumab-treated patients
(Tysabri 2016). The assay used to detect the presence of
JCV antibodies, Stratify JCV® DxSelect™ (Focus
Diagnostics, Cypress, CA, USA), reports a binary output
of positive or negative. Additional research described in
2013 (Plavina et al. 2013) and published in 2014 (Plavina
et al. 2014) demonstrated that JCV index values could
further stratify PML risk in natalizumab-treated anti-JCV
antibody positive patients without prior exposure to
immunosuppressants.
The estimated US incidence of PML risk table
(Tysabri 2016) helps to inform health care providers
(HCPs) and thei r pa t ients about PML risk on
natalizumab treatment. It is based on three identified risk
factors: the presence of anti-JCV antibodies, the duration
of treatment (especially beyond 2 years), and prior treat-
ment with an immunosuppressant. Benefit/risk assess-
ment is complex and varies among HCPs and patients.
The algorithm exists to assist HCPs in risk stratification
of PML based on the established risk factors. On the
assumption that risk stratification has altered patient
management, the outcome of potentially changing behav-
ior can only be assessed retrospectively and after a sig-
nificant period of time.
Dr. Werner has reported (Werner and Huang 2016)
that in the nearly 4 years since the antibody test became
available as a means of risk stratification, there has been
only a modest reduction in the incidence of PML arising
from natalizumab treatment (based on data from
February 2011 to January 2016).
Using a broader data set of PML incidence extending
from November 2009 to June 2016 (Biogen, data on
file), we generated a new graphical representation of
PML incidence in natalizumab-treated patients (Fig. 1).
While our analysis is similar to that of Dr. Werner, we
also applied a statistical method to approximate the plot-
ted curve, as described below. The two lines drawn in
red and green were found to be the best-fit lines. (The
statistical method demonstrated that the best fit is not
substantially improved by approximating the curve with
three or more lines.) The differences between the associ-
ated slopes are statistically significant (p < 0.0001). As
shown on the graph, PML incidence increased at a rate
of 0.067 per month from December 2009 to September
2013. From September 2013 to June 2016, the slope of
the line increased at a rate of 0.027 per month,
representing a more than 50 % decrease in the slope after
September 2013. The mathematically derived break
point, which can be tested at any point along the curve,
was optimized at the September 2013 time point, approx-
imately 18 months after introduction of the JCV antibody
assay.
While it is not possible to assign causal relationships
for the slope reduction, a significant reduction in PML
* Denise Campagnolo
denise.campagnolo@biogen.com
1 Biogen, 14 Cambridge Center, Cambridge, MA 02142, USA
J. Neurovirol. (2016) 22:880–881
DOI 10.1007/s13365-016-0482-z
incidence rise is observed beginning in September 2013
and continuing through June 2016. Further investigation
may elucidate factors that have influenced this change over
time in PML incidence.
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Trend-line slope prior to break point: 0.0670 (95% CI, 0.0658–0.0683)
Trend-line slope after break point: 0.0270 (95% CI, 0.0249–0.0291)
Comparison of slopes: p < 0.0001
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Fig. 1 Incidence of PML in
natalizumab-treated patients from
2009 to 2016. Piecewise
regression analysis, incorporating
changing points, was employed to
identify the optimal break point
and to estimate the slopes.
Statistical testing shows a two-
piece regression is significantly
better than one-piece regression,
whereas three-piece regression
does not give a significantly better
fit for the data than two-piece
regression. CI confidence interval
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